Abstract
IntroductionCabozantinib monotherapy is an option for treatment of advanced renal cell carcinoma (RCC). However, cabozantinib dose modification and discontinuation due to symptomatic adverse events (AEs) remains a challenge. The use...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have